Jessica Lynn Pedersen, OTD, OTR/L | |
200 1st St Sw, Rochester, MN 55905-0002 | |
(507) 284-2511 | |
Not Available |
Full Name | Jessica Lynn Pedersen |
---|---|
Gender | Female |
Speciality | Occupational Therapist |
Location | 200 1st St Sw, Rochester, Minnesota |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1346852688 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225X00000X | Occupational Therapist | 20531 (California) | Secondary |
225X00000X | Occupational Therapist | 106328 (Minnesota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jessica Lynn Pedersen, OTD, OTR/L 200 1st St Sw, Rochester, MN 55905-0002 Ph: () - | Jessica Lynn Pedersen, OTD, OTR/L 200 1st St Sw, Rochester, MN 55905-0002 Ph: (507) 284-2511 |
News Archive
Taiwanese researchers find that virological response to tenofovir disoproxil fumarate in treatment-experienced patients with chronic hepatitis B virus infection can vary depending on the nucleos(t)ide analogue the patient is resistant to.
A new study finds that women who suffer from migraine headaches may be about 40% more likely to develop depression than women who have never had migraines. The results will be presented in April at the annual meeting of the American Academy of Neurology at New Orleans.
Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company's lead compound for Alzheimer's disease, has been approved by the German regulatory health authority, BfArM. The Phase I trial of ANAVEX 2-73, which includes testing in healthy human volunteers, will commence immediately. In this Phase I program Anavex will assess the safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics of ANAVEX 2-73.
In patients with pre-existing heart or lung disease, being exposed to high levels of traffic-related air pollutants is associated with reduced heart rate variability —a risk factor for sudden cardiac death, reports a study in the July Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.
Researchers based in Paris, France, have explored the potential use of zebrafish larvae as animal models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These larvae are small and cheap, so could prove a suitable medium for rapid mass testing of the disease.
› Verified 4 days ago
Amy L Krekelberg, OT Occupational Therapist Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Danielle Anshus, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Erika Hope Mckeever, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Deborah Engen, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Susan D Hansen, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Mary B Clark, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Sara Kathleen Tallman, O.T.D. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |